Picture loading failed.

Anti-DLL3 therapeutic antibody (Pre-made Rovalpituzumab biosimilar,Whole mAb ADC) is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic).

Rovalpituzumab tesirine (Rova-T) is an experimental antibody-drug conjugate targeting the protein DLL3 on tumor cells. It was originally developed by Stemcentrx and was purchased by AbbVie.[3] It was tested for use in small-cell lung cancer, but development was terminated after unsuccessful phase III trial.

Order informatioin


Delivery impact due to the Coronavirus Outbreak

With the COVID-19 outbreak in the world, many flights have been cancelled. In order for the customer to receive the goods properly, we use the FedEx Customized Freight (FCF) of Fedex which demands a higher fee. If the delivery fee is more expensive in your area, we will contact you by mail.

Catalog No. Package Price(In USD) Qty (Quantity) Sum(In USD)
GMP-Bios-ab-497-1mg 1mg 3090
GMP-Bios-ab-497-10mg 10mg 21890
GMP-Bios-ab-497-100mg 100mg 148000
GMP-Bios-ab-497-xmg >100mg Inquiry
Shipping Cost: 760.00
Total:



Description

Products Name (INN Index) Anti-DLL3 therapeutic antibody (Pre-made Rovalpituzumab biosimilar,Whole mAb ADC)
INN Name Rovalpituzumab
TargetDLL3
FormatWhole mAb ADC
DerivationHumanized
Species ReactivityHuman
CH1 IsotypeIgG1
VD LCKappa
Highest_Clin_Trial (Jan '20)Phase-III
Est. StatusDiscontinued
100% SI StructureNone
99% SI StructureNone
95-98% SI StructureNone
Year Proposed2015
Year Recommended2016
CompaniesBristol-Myers Squibb;Stemcentrx
Conditions Approvedna
Conditions Activena
Conditions DiscontinuedSmall cell lung cancer;Solid tumours
Development Techna